Hae Il Cheong

Prof. Hae Il Cheong

Seoul National University Children's Hospital
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2007 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
HCHee Yeon Cho
Hee Yeon Cho
BLBum Hee Lee
Bum Hee Lee
HCHyun Jin Choi
Hyun Jin Choi
IHIl Soo Ha
Il Soo Ha
YCYong Choi
Yong Choi
HCHae Il Cheong
Hae Il Cheong

16 February 2008 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
HCHyun Jin Choi
Hyun Jin Choi
BLBeom Hee Lee
Beom Hee Lee
JKJu Hyung Kang
Ju Hyung Kang
HJHyoen Joo Jeong
Hyoen Joo Jeong
KMKyung Chul Moon
Kyung Chul Moon
HCHae Il Cheong
Hae Il Cheong

1 May 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
PPPeong Gang Park
Peong Gang Park
CHChe Ry Hong
Che Ry Hong
EKEunjeong Kang
Eunjeong Kang
MPMinsu Park
Minsu Park
HLHajeong Lee
Hajeong Lee
HKHee Gyung Kang
Hee Gyung Kang

11 November 2011 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
HLHyunKyung Lee
HyunKyung Lee
KHKyoung Hee Han
Kyoung Hee Han
SLSe Eun Lee
Se Eun Lee
SKSeong Heon Kim
Seong Heon Kim
HKHee Gyung Kang
Hee Gyung Kang
HCHae Il Cheong
Hae Il Cheong

29 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAlexandra Barry
Alexandra Barry
MMMichelle T. McNulty
Michelle T. McNulty
XJXiaoyuan Jia
Xiaoyuan Jia
YGYask Gupta
Yask Gupta
HDHanna Debiec
Hanna Debiec
MSMatthew G. Sampson
Matthew G. Sampson
Pediatric steroid-sensitive nephrotic syndrome (pSSNS) is the most common childhood glomerular disease. Previous genome-wide association studies (GWAS) identified a risk locus in the HLA Class II region and three additional independent risk loci. But the genetic architecture of pSSNS, and its genetically driven pathobiology, is largely unknown. Here, we conduct a multi-population GWAS meta-analysis in 38,463 participants (2440 cases). We then conduct conditional analyses and population specific GWAS. We discover twelve significant associations—eight from the multi-population meta-analysis (four novel), two from the multi-population conditional analysis (one novel), and two additional novel loci from the European meta-analysis. Fine-mapping implicates specific amino acid haplotypes in HLA-DQA1 and HLA-DQB1 driving the HLA Class II risk locus. Non-HLA loci colocalize with eQTLs of monocytes and numerous T-cell subsets in independent datasets. Colocalization with kidney eQTLs is lacking but overlap with kidney cell open chromatin suggests an uncharacterized disease mechanism in kidney cells. A polygenic risk score (PRS) associates with earlier disease onset. Altogether, these discoveries expand our knowledge of pSSNS genetic architecture across populations and provide cell-specific insights into its molecular drivers. Evaluating these associations in additional cohorts will refine our understanding of population specificity, heterogeneity, and clinical and molecular associations.

3 February 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JLJiwon M. Lee
Jiwon M. Lee
KNKandai Nozu
Kandai Nozu
DCDae Eun Choi
Dae Eun Choi
HKHee Gyung Kang
Hee Gyung Kang
IHIl-Soo Ha
Il-Soo Ha
HCHae Il Cheong
Hae Il Cheong
Alport syndrome (AS) is one of the most frequent hereditary nephritis leading to end-stage renal disease (ESRD). Although X-linked (XLAS) inheritance is the most common form, cases with autosomal recessive inheritance with mutations in COL4A3 or COL4A4 are being increasingly recognized. A systematic review was conducted on autosomal recessive Alport syndrome (ARAS). Electronic databases were searched using related terms (until Oct 10th, 2018). From 1601 articles searched, there were 26 eligible studies with 148 patients. Female and male patients were equally affected. About 62% of patients had ESRD, 64% had sensorineural hearing loss (SNHL) and 17% had ocular manifestation. The median at onset was 2.5 years for hematuria (HU), 21 years for ESRD, and 13 years for SNHL. Patients without missense mutations had more severe outcomes at earlier ages, while those who had one or two missense mutations had delayed onset and lower prevalence of extrarenal manifestations. Of 49 patients with kidney biopsy available for electron microscopy (EM) pathology, 42 (86%) had typical glomerular basement membrane (GBM) changes, while 5 (10%) patients showed GBM thinning only. SNHL developed earlier than previously reported. There was a genotype phenotype correlation according to the number of missense mutations. Patients with missense mutations had delayed onset of hematuria, ESRD, and SNHL and lower prevalence of extrarenal manifestations.